🇺🇸 FDA

Intelligence Platform

Patents

Browse 837 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 9789184

Anti-EGFR antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9771414

Human antibodies to ebola virus glycoprotein

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 26 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9751932

Anti-big-endothelin-1 (big-ET-1) antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 05 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 31 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9751921

Apelin fusion proteins and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 05 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 31 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9724411

Methods for treating hypercholesterolemia and reducing LDL-C using antibodies to PCSK9

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 08 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 03 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9718872

Human antibodies to middle east respiratory syndrome—coronavirus spike protein

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9718881

Anti-Activin A antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9708386

Modified chimeric polypeptides with improved pharmacokinetic properties

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9700027

Non-human animals having a humanized signal-regulatory protein gene

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9700025

Genetically modified major histocompatibility complex animals

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9688764

Methods of treating breast cancer by administering anti-human prolactin receptor (PRLR) an

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 27 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9687566

Low affinity FCGR deficient mice

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 27 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9675692

Stabilized formulations containing anti-DLL4 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 13 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9669069

Use of a VEGF antagonist to treat angiogenic eye disorders

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 06 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9657102

Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 23 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 18 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9657099

Anti-glucagon antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 23 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 18 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9655352

Humanized M-CSF mice

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 23 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 18 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9650444

Anti-PDGFR-beta antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 16 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 11 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9644018

Antibody modulators of APLNR

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 09 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 04 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9637535

IL-33 antagonists and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 02 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9636400

VEGF specific fusion protein antagonist formulations

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 02 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9592271

Angiopoietin-based interventions for treating cerebral malaria

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9587029

Human antibodies to the glucagon receptor and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9580489

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted